It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Equillium Inc (EQ) USD0.0001

Sell:$5.95 Buy:$6.20 Change: $0.06 (1.00%)
Market closed |  Prices as at close on 15 June 2021 | Switch to live prices |
Change: $0.06 (1.00%)
Market closed |  Prices as at close on 15 June 2021 | Switch to live prices |
Change: $0.06 (1.00%)
Market closed |  Prices as at close on 15 June 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Equillium, Inc. is a biotechnology company. The Company develops products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its initial product candidate, EQ001 (itolizumab), is a clinical-stage, monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in the modulation of effector T cells, or Teff cells. Activated Teff cells drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. EQ001, disease modifying treatment for multiple severe immuno-inflammatory disorders. It plans to initiate a Phase Ib/II clinical trial of EQ001 for the treatment of acute graft-versus-host disease, or aGVHD.

Contact details

2223 Avenida de La Playa Ste 105
United States
+1 (858) 4125302

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$173.95 million
Shares in issue:
29.04 million
United States
US dollar

Key personnel

  • Daniel Bradbury
    Executive Chairman of the Board
  • Bruce Steel
    President, Chief Executive Officer, Director
  • Jason Keyes
    Chief Financial Officer
  • Christine Zedelmayer
    Chief Operating Officer, Senior Vice President
  • Dolca Thomas
    Executive Vice President of Research & Development and Chief Medical Officer
  • Stephen Connelly
    Chief Scientific Officer, Director
  • Maple Fung
    Vice President - Clinical Development
  • Matthew Ritter
    Vice President - Corporate Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.